| Target Price | €43.64 |
| Price | €39.99 |
| Potential | 9.14% |
| Number of Estimates | 18 |
| 18 Analysts have issued a price target Qiagen 2027 . The average Qiagen target price is €43.64. This is 9.14% higher than the current stock price. The highest price target is €51.21 28.08% , the lowest is €38.89 2.73% . | |
| A rating was issued by 24 analysts: 12 Analysts recommend Qiagen to buy, 12 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Qiagen stock has an average upside potential 2027 of 9.14% . Most analysts recommend the Qiagen stock at Buy or hold. |
25 Analysts have issued a sales forecast Qiagen 2025 . The average Qiagen sales estimate is €1.8b . This is 2.28% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €1.9b 5.90% , the lowest is €1.7b 3.66% .
This results in the following potential growth metrics:
| 2024 | €1.7b | 0.66% |
|---|---|---|
| 2025 | €1.8b | 7.07% |
| 2026 | €1.9b | 6.14% |
| 2027 | €2.0b | 6.27% |
| 2028 | €2.3b | 10.38% |
| 2029 | €2.4b | 7.93% |
| 2030 | €2.9b | 17.88% |
22 Analysts have issued an Qiagen EBITDA forecast 2025. The average Qiagen EBITDA estimate is €674m . This is 38.87% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €744m 53.38% , the lowest is €581m 19.84% .
This results in the following potential growth metrics and future EBITDA Margins:
| 2024 | €432m | 10.65% |
|---|---|---|
| 2025 | €674m | 56.08% |
| 2026 | €717m | 6.36% |
| 2027 | €781m | 9.03% |
| 2028 | €844m | 8.01% |
| 2029 | €892m | 5.64% |
| 2024 | 25.51% | 9.92% |
|---|---|---|
| 2025 | 37.18% | 45.77% |
| 2026 | 37.26% | 0.22% |
| 2027 | 38.23% | 2.60% |
| 2028 | 37.40% | 2.17% |
| 2029 | 36.61% | 2.11% |
25 Qiagen Analysts have issued a net profit forecast 2025. The average Qiagen net profit estimate is €447m . This is 28.85% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €464m 33.68% , the lowest is €427m 23.19% .
This results in the following potential growth metrics and future Net Margins:
| 2024 | €71.5m | 75.51% |
|---|---|---|
| 2025 | €447m | 524.87% |
| 2026 | €481m | 7.58% |
| 2027 | €527m | 9.65% |
| 2028 | €591m | 12.00% |
| 2029 | €650m | 10.10% |
| 2024 | 4.23% | 75.67% |
|---|---|---|
| 2025 | 24.66% | 483.59% |
| 2026 | 25.00% | 1.38% |
| 2027 | 25.79% | 3.16% |
| 2028 | 26.17% | 1.47% |
| 2029 | 26.70% | 2.03% |
25 Analysts have issued a Qiagen forecast for earnings per share. The average Qiagen EPS is €2.06 . This is 30.38% higher than earnings per share in the financial year 2024. The highest EPS forecast is €2.14 35.44% , the lowest is €1.97 24.68% .
This results in the following potential growth metrics and future valuations:
| 2024 | €0.33 | 74.81% |
|---|---|---|
| 2025 | €2.06 | 524.24% |
| 2026 | €2.22 | 7.77% |
| 2027 | €2.43 | 9.46% |
| 2028 | €2.72 | 11.93% |
| 2029 | €3.00 | 10.29% |
| Current | 24.60 | 82.41% |
|---|---|---|
| 2025 | 18.86 | 23.34% |
| 2026 | 17.53 | 7.05% |
| 2027 | 15.98 | 8.84% |
| 2028 | 14.27 | 10.70% |
| 2029 | 12.96 | 9.18% |
Based on analysts' sales estimates for 2025, the Qiagen stock is valued at an EV/Sales of 4.97 and an P/S ratio of 4.76 .
This results in the following potential growth metrics and future valuations:
| Current | 5.08 | 10.72% |
|---|---|---|
| 2025 | 4.97 | 2.24% |
| 2026 | 4.68 | 5.78% |
| 2027 | 4.40 | 5.90% |
| 2028 | 3.99 | 9.40% |
| 2029 | 3.70 | 7.34% |
| 2030 | 3.14 | 15.17% |
| Current | 4.87 | 12.61% |
|---|---|---|
| 2025 | 4.76 | 2.23% |
| 2026 | 4.48 | 5.78% |
| 2027 | 4.22 | 5.90% |
| 2028 | 3.82 | 9.40% |
| 2029 | 3.54 | 7.35% |
| 2030 | 3.00 | 15.17% |
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Dec 15 2025 |
| Citigroup |
Buy
➜
Neutral
|
Downgrade | Dec 11 2025 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Oct 02 2025 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Aug 07 2025 |
| B of A Securities |
Buy
➜
Buy
|
Unchanged | Jun 26 2025 |
| Barclays |
➜
Overweight
|
Initiated | Jun 24 2025 |
| Baird |
Neutral
➜
Neutral
|
Unchanged | Apr 21 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Dec 15 2025 |
|
Downgrade
Citigroup:
Buy
➜
Neutral
|
Dec 11 2025 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Oct 02 2025 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Aug 07 2025 |
|
Unchanged
B of A Securities:
Buy
➜
Buy
|
Jun 26 2025 |
|
Initiated
Barclays:
➜
Overweight
|
Jun 24 2025 |
|
Unchanged
Baird:
Neutral
➜
Neutral
|
Apr 21 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


